SCHEMBL3824920

SCHEMBL3824920

CCOC(=O)c1nc(C)c(C(=O)O)s1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
HPGD P15428 4/20 0.49
TSHR P16473 2/20 0.49
NPC1 O15118 2/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CDC7 O00311 2/20 0.46
DBF4 Q9UBU7 2/20 0.46
CYP1A2 P05177 1/20 0.45
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
CYP2C9 P11712 1/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6114078 0.86 ALDH1A1 (0.53) ALDH1A1HPGDNPC1MAPTRAB9A
SCHEMBL25297796 0.86 ALDH1A1 (0.56) ALDH1A1HPGDTSHRNPC1MAPT
SCHEMBL3827730 0.85 ALDH1A1 (0.50) ALDH1A1HPGDNPC1MAPTRAB9A
SCHEMBL6114364 0.82 ALDH1A1 (0.46) ALDH1A1HPGDTSHRNPC1MAPT
SCHEMBL3828334 0.81 ALDH1A1 (0.48) ALDH1A1HPGDTSHRNPC1MAPT
SCHEMBL1503950 0.80 ALDH1A1 (0.45) ALDH1A1HPGDNPC1MAPTHSD17B10
SCHEMBL27848208 0.79 ALDH1A1 (0.60) ALDH1A1HPGDTSHRNPC1MAPT
SCHEMBL3655946 0.79 ALDH1A1 (0.61) ALDH1A1HPGDTSHRNPC1MAPT
SCHEMBL289991 0.77 ALDH1A1 (0.43) ALDH1A1HPGDNPC1MAPTRAB9A
SCHEMBL3823404 0.76 ALDH1A1 (0.45) ALDH1A1HPGDTSHRNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 EP disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
CN-116615425-A Compounds and compositions as Sppl2a inhibitors 诺华股份有限公司 2023-08-18 CN disclosed
EP-4214210-A1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2023-07-26 EP disclosed
EP-2096111-A1 PYRAZOLES AND USE THEREOF AS DRUGS Japan Tobacco Inc. (JP) 2009-09-02 EP disclosed
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO, INC. (JP) 2009-02-05 US disclosed
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO, INC. (JP) 2009-02-05 US disclosed
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF JAPAN TOBACCO, INC. (JP) 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 ALDH1A1 3565/4885HPGD 2716/4885TSHR 4010/4885
US-20090036450-A1 PYRAZOLE COMPOUNDS AND USE THEREOF PYGL, GYS2, G6PC1 ALDH1A1 775/4885HPGD 675/4885TSHR 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.